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Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether alis-
kiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure
(HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-
discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM).
Methods
and results
ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319;
placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death
or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-
type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding riskof hyperkalaemia, renal impairment, and
hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death
or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P ¼ 0.08 for interaction),
but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64–0.99; DM: HR: 1.16, 95% CI: 0.91–1.47;
P ¼ 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline
DM (non-DM: HR: 0.69, 95% CI: 0.50–0.94; DM: HR: 1.64, 95% CI: 1.15–2.33; P, 0.01 for interaction). Among
non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone
through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldoster-
one relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium
≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71–1.93; DM: HR: 2.39, 95%
CI: 1.30–4.42; P ¼ 0.07 for interaction).
Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren
to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and
biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes.
Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF
patients without DM.
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Introduction
There are over 1 million primary hospitalizations for heart failure
(HHF) annually in the USA alone,1 and this population continues to
experience poor post-discharge outcomes despite available therap-
ies.2 Theheterogeneityof clinical profilesamong thesepatients iswell
established and the majority have a history of cardiovascular (CV)
and non-CV comorbidities.2,3 Approximately 40% of HHF patients
havea historyof diabetes mellitus (DM)and observational andclinical
trial data have explored the associated prognostic implications.4,5
Recently, the Aliskiren Trial on Acute Heart Failure Outcomes
(ASTRONAUT) confirmed the high prevalence of DM among HHF
patients with reduced left ventricular ejection fraction (LVEF).6 In
this study, the addition of aliskiren to standard therapy had no
significant effect on CV death or heart failure (HF) rehospitalization
within 6 or 12 months. Although the overall study results were
neutral, pre-specified subgroup analysis found the effect of the study
drug on all-cause death within 12 months to differ by the presence
of comorbid DM, with aliskiren associated with a higher risk of death
in diabetics and lower risk of death in non-diabetics. These data
wereconsistent withprevious reportsofpooroutcomeswith aliskiren
in diabetics already taking renin–angiotensin–aldosterone system
(RAAS) inhibitors.7 The ASTRONAUT trial affords the opportunity
to perform an in-depth characterization of patients with HHF by
the presence or absence of DM to better understand this possible
bidirectional effect of aliskiren on outcomes. Given the potentially
improved survival with aliskiren among nearly 60% of ASTRONAUT
patients without diabetes and the current lack of therapies proven
to improve outcomes in HHF, these data deserve further analysis.
Methods
Study design
The study design8 and primary results of the ASTRONAUT trial
have been previously described.6 Briefly, the ASTRONAUT trial was a
prospective, multicentre, multinational, randomized, double-blind,
placebo-controlled trial investigating the role of oral aliskiren, a direct
renin inhibitor, on outcomes among HHF patients. Patients were rando-
mized a median 5 days after hospital admission to 150 mg daily (increased
to 300 mg daily as tolerated) of aliskiren or placebo, in addition to stand-
ard therapy. All patients were 18 years of age or older with LVEF ≤ 40%,
elevatednatriureticpeptides [B-typenatriuretic peptide (BNP)≥400 pg/
mL or N-terminal pro-B-type natriuretic peptide (NT-proBNP)
≥1600 pg/mL], and signs and symptoms of fluid overload that necessi-
tated hospitalization. Before randomization, patients were required
to be haemodynamically stable, defined as systolic blood pressure
≥110 mmHg for at least 6 h and no use of intravenous vasodilators
(except nitrates) or intravenous inotropes from time of hospital presen-
tation to randomization. Exclusion criteria included estimated glomeru-
lar filtration rate (eGFR) ,40 mL/min/1.73 m2, serum potassium level
.5.0 mEq/L, hyponatraemia ,130 mEq/L, recent myocardial infarction
(MI), cardiac surgery or stroke, and comorbid conditions with expected
survival,3 years. Local institutional review boards or ethics committees
ateachcentreapprovedthe studyprotocol andpatients providedwritten
informed consent for participation. Efficacy analysis by patient history of
DM (as determined by the investigator) was a protocol pre-specified sub-
group analysis prospectively planned prior to database lock and included
all patients from both treatment arms used for efficacy analysis. Safety
analysis by baseline DM status was performed post hoc.
The primaryendpoint inASTRONAUTwasthe firstoccurrence of CV
death or HF rehospitalization within 6 months after randomization. Sec-
ondary endpoints included CV death or HF rehospitalization within 12
months (key secondary endpoint), first CV event (defined as CV death,
HF rehospitalization, non-fatal MI, non-fatal stoke, and resuscitated
sudden death) within 12 months, all-cause death within 6 and 12
months, and change from baseline in NT-proBNP level at 1, 6, and 12
months. Additional data regarding biomarker levels (plasma renin activ-
ity, plasma troponin I, plasma aldosterone) were also collected and ana-
lysed. An independent, clinical events committee adjudicated specific
causes of death and hospitalization (Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USA).
Statistical analysis
Categorical variables are reported as number (percentage), while
continuous variables are expressed as means+ standard deviation if
normally distributed or as median (inter-quartile range) if not normally
distributed.
The time-to-event data were assumed to follow a proportional hazard
model and hazard ratios (HR) and corresponding 95% confidence inter-
vals (CI) are provided. The assumption of proportional hazards was veri-
fied using a Cox proportional hazards regression model which included
treatment and a time-dependent explanatory variable created through
the interaction between log time and treatment. The estimate of the
interaction term was presented in terms of the change in effect from 1
month to the next. In addition, a plot of the log–log survivor function
vs. log time for each treatment group was performed. Approximate par-
allelism between the curves for treatment groups provided supportive
evidence of the proportional hazards assumption. Analyses were per-
formed for the primary endpoint and the selected secondary endpoints
(CV death or HF rehospitalization within 12 months, all-cause death
within 6 and 12 months, first CV event within 12 months). Testing for
interaction between all endpoints and baseline DM status was per-
formed. Cumulative event rate estimates (1 – estimated survival func-
tion, described in %) vs. time of follow-up (in years) were calculated
based on the Kaplan–Meier estimates.
Biomarker data were analysed for diabetic and non-diabetic groups,
and changes in NT-proBNP (pg/mL), plasma renin activity (ng/mL/h),
plasma troponin I (ng/mL), and plasma aldosterone (pmol/L) were calcu-
lated using log-transformation and summarized in a geometric mean with
95% CI on a geometric mean. In addition, a repeatedmeasurement model
was performed on change from baseline log-transformed for biomarker
variables. All the results were back-transformed to provide the geomet-
ric least squaresmeans (presentedas a ratio to baseline), the ratio for alis-
kiren vs. placebo, and the 95% CI around the ratio for each time point
(1, 6, and 12 months).
Adverse events of special interest including hyperkalaemia, renal im-
pairment or renal failure, and hypotension and corresponding rates of
treatment discontinuation for these events were calculated. Additionally,
incidence of post-baseline potassium ≥6 mmol/L and eGFR ,30 mL/
min/1.73 m2 were summarized by treatment group. Relative risk and cor-
responding 95% CI were used in treatment comparison, and interaction
analysis was performed by baseline DM status.
The cohort used for efficacy analysis was from the full-analysis set,
defined as all randomized patients who received at least 1 dose of
the study drug. Following the intent-to-treat principle, patients were
analysed according to the treatment assigned at randomization. Safety
was analysed in all patients who received study drug and had at least
one post-baseline safety assessment. All statistical analyses were
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Table 1 Baseline characteristics of non-diabetic and diabetic patients
Non-diabetics Diabetics
Characteristic Aliskiren
(n5 489)
Placebo
(n 5 464)
Aliskiren
(n5 319)
Placebo
(n5 343)
Age (years), mean (SD) 64.1 (13.3) 63.4 (13.0) 65.6 (11.0) 66.0 (10.1)
Male, n (%) 394 (80.6) 345 (74.4) 243 (76.2) 265 (77.3)
Race, n (%)
Caucasian 342 (69.9) 325 (70.0) 232 (72.7) 241 (70.3)
Black 22 (4.5) 24 (5.2) 14 (4.4) 18 (5.2)
Asian 101 (20.7) 94 (20.3) 66 (20.7) 75 (21.9)
Other 24 (4.9) 21 (4.5) 7 (2.2) 9 (2.6)
NYHA class at Visit 1, n (%)
III 304 (62.2) 281 (60.6) 194 (60.8) 204 (59.5)
IV 185 (37.8) 183 (39.4) 125 (39.2) 139 (40.5)
NYHA class at Visit 2, n (%)
I 14 (2.9) 9 (1.9) 3 (0.9) 8 (2.3)
II 166 (33.9) 152 (32.8) 101 (31.7) 94 (27.4)
III 268 (54.8) 258 (55.6) 173 (54.2) 204 (59.5)
IV 35 (7.2) 38 (8.2) 33 (10.3) 33 (9.6)
Ischaemic heart failure aetiology, n (%) 287 (58.7) 248 (53.4) 233 (73.0) 259 (75.5)
Prior heart failure hospitalization, n (%) 309 (63.2) 313 (67.5) 230 (72.1) 232 (67.6)
Ejection fraction (%), mean (SD) 28 (7.3) 27 (7.5) 28 (7.3) 28 (6.9)
Systolic blood pressure (mmHg), mean (SD) 123 (12.8) 123 (12.2) 125 (14.2) 124 (13.8)
Heart rate (b.p.m.), mean (SD) 77 (16.0) 78 (16.5) 79 (16.0) 78 (15.3)
eGFR (mL/min/1.73 m2), mean (SD), Visit 2 68.5 (20.4) 67.0 (19.9) 65.5 (19.1) 64.9 (20.0)
eGFR (mL/min/1.73 m2) group, n (%), Visit 2
,60 181 (37.0) 169 (36.4) 137 (42.9) 146 (42.6)
≥60 291 (59.5) 275 (59.3) 166 (52.0) 183 (53.4)
NT-proBNP (pg/mL), median (IQR), Visit 1 4471 (2840–8540) 4472 (2715–8924) 4015 (2615–6679) 3738 (2682–7461)
NT-proBNP (pg/mL), median (IQR), Visit 2 2851 (1510–5344) 2651 (1555–5257) 2736 (1523–5097) 2699 (1536–5074)
BNP (pg/mL), mean (IQR), Visit 1 936 (592–1650) 842 (533–1570) 908 (541–1567) 866 (558–1655)
BNP (pg/mL), mean (IQR), Visit 2 466 (239–900) 437 (220–910) 480 (238–920) 390 (206–773)
Sodium (mmol/L), mean (SD) 139 (3.7) 139 (3.8) 139 (3.3) 138 (3.8)
Potassium (mmol/L), mean (SD) 4.3 (0.8) 4.3 (0.7) 4.3 (0.5) 4.3 (0.6)
Troponin I (ng/mL), median (IQR) 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.0 (0.0–0.1)
Atrial fibrillation on ECG, n (%), Visit 2 154 (31.5) 148 (31.9) 88 (27.6) 96 (28.0)
Medical history, n (%)
Hypertension 353 (72.2) 330 (71.1) 259 (81.2) 283 (82.5)
Coronary artery disease 240 (49.1) 203 (43.8) 203 (63.6) 235 (68.5)
Renal insufficiency 67 (13.3) 79 (17.0) 93 (29.2) 93 (27.1)
Chronic obstructive pulmonary disease 97 (19.8) 78 (16.8) 71 (22.3) 76 (22.2)
Background therapies, n (%)
Diuretic (not including mineralocorticoid receptor antagonist) 469 (95.9) 445 (95.9) 306 (95.9) 328 (95.6)
Angiotensin-converting enzyme inhibitors 324 (66.3) 318 (68.5) 203 (63.6) 211 (61.5)
Angiotensin II receptor blockers 87 (17.8) 65 (14.0) 72 (22.6) 80 (23.3)
Beta-blockers 385 (78.7) 391 (84.3) 275 (86.2) 282 (82.2)
Mineralocorticoid receptor antagonist 276 (56.4) 281 (60.6) 172 (53.9) 192 (56.0)
BNP, B-type natriuretic peptide; b.p.m., beat per minute; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; IQR, inter-quartile range; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.
Data pertain to Visit 2 unless otherwise specified. Visit 1 refers to time point when the diagnosis of worsening chronic heart failure and studyeligibility were confirmed. Visit 2 refers to
time point when stabilized patients were randomized to aliskiren or placebo, in addition to standard therapy.
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performed using SAS version 9.2 (SAS Institute), and two-sided P, 0.05
was considered to be statistically significant.
Results
Baseline characteristics
The current study included 1615 patients from the final ASTRO-
NAUT efficacy analysis cohort, of which 953 patients were without
a documented history of DM (59%). The median follow-up in the
overall population was 11.3 months (inter-quartile range 9.1–12.4
months). Table 1 describes the baseline demographic, clinical, and
laboratory profile for all patients in this analysis by underlying DM
history and treatment group. Baseline characteristics by treatment
arm did not significantly differ by DM status with the following excep-
tions: age, ischaemic HF aetiology, systolic blood pressure, eGFR,
serum sodium, and angiotensin II receptor blocker (ARB) use.
Among patients with DM, 42% were receiving insulin therapy and
53% were receiving oral antihyperglycemic agents.
Study endpoints
Outcome analyses for non-diabetic and diabetic patients are dis-
played in Table 2. Overall, the influence of aliskiren on the primary
endpoint of CV death or HF rehospitalization within 6 months did
not significantly differ by DM status (P ¼ 0.08 for interaction). The
effect of aliskiren on 12-month CV death or HF rehospitalization
(P ¼ 0.03 for interaction), first CV event within 12 months
(P ¼ 0.02 for interaction) and 12-month all-cause death (P, 0.01
for interaction) significantly differed according to baseline history
of DM. There was a borderline significant interaction between treat-
ment arm and diabetes status for all-cause death within 6 months
(P ¼ 0.05 for interaction).
Among non-diabetics, 102 patients in the aliskiren group (20.9%)
and 114 patients in the placebo group (24.6%) experienced the
primary endpoint (HR: 0.80; 95% CI: 0.61–1.04) (Figure 1). In
regard to 12-month secondary endpoints, non-diabetics receiving
aliskiren were significantly less likely to experience CV death or HF
hospitalization (HR: 0.80; 95% CI: 0.64–0.99), first CV event
(HR: 0.75; 95% CI: 0.61–0.94) and all-cause death (HR: 0.69; 95%
CI: 0.50–0.94) when compared with placebo (Figure 2).
Similar to the non-diabetic group, there was no significant differ-
ence in the rate of the primary endpoint between treatment
groups among patients with DM (HR: 1.13; 95% CI: 0.86–1.50).
However, diabetics receiving aliskiren were significantly more likely
to die within 12 months (HR: 1.64; 95% CI: 1.15–2.33).
Adjudicated causes of death
Table 3 presents descriptive data on adjudicated causes of death by
treatment arm and DM status for all the patients included in efficacy
analysis plus three additional placebo patients (one patient missing
informed consent, two patients with associated Good Clinical Prac-
tice violations).During the double-blind period, the rates of CV death
among non-diabetics receiving aliskiren and placebo were 13.7 and
18.9%, respectively. Major contributors to reduced CV death with
aliskiren were decreased rates of pump failure (aliskiren 4.7%;
placebo 7.1%) and presumed CV death (aliskiren 0.8%; placebo
2.2%). In contrast, among diabetic patients, aliskiren was associated
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Table 2 Study endpoints by baseline diabetes status
Endpoint Aliskiren, n (%)
Non-DM (n5 489)
DM (n 5 319)
Placebo, n (%)
Non-DM (n 5 464)
DM (n 5 343)
Hazard ratio
(95% CI)
P for interaction (two-sided)
Primary endpoint (6 months)
CV death or HF rehospitalization
Non-DM 102 (20.9) 114 (24.6) 0.80 (0.61–1.04)
DM 99 (31.0) 100 (29.2) 1.13 (0.86–1.50) 0.08
Secondary endpoints (12 months, unless otherwise specified)
CV death or HF rehospitalization
Non-DM 148 (30.3) 165 (35.6) 0.80 (0.64–0.99)
DM 135 (42.3) 136 (39.7) 1.16 (0.91–1.47) 0.03
First CV event
Non-DM 154 (31.5) 177 (38.1) 0.75 (0.61–0.94)
DM 139 (43.6) 144 (42.0) 1.11 (0.88–1.40) 0.02
All-cause death (6 months)
Non-DM 43 (8.8) 51 (11.0) 0.75 (0.50–1.13)
DM 42 (13.2) 38 (11.1) 1.38 (0.88–2.15) 0.05
All-cause death
Non-DM 72 (14.7) 91 (19.6) 0.69 (0.50–0.94)
DM 72 (22.6) 57 (16.6) 1.64 (1.15–2.33) ,0.01
CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; HF, heart failure.
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with a higher rate of CV death (aliskiren 21.0%; placebo 16.2%), pump
failure (aliskiren 9.7%; placebo 6.7%) and sudden death (aliskiren
5.6%; placebo 4.3%). Rates of non-CV death in ASTRONAUT
were low in both non-diabetic and diabetic patients.
Effect on biomarkers
Theeffectsof aliskirenonCVbiomarkers in patientswith andwithout
baseline DM are displayed in Table 4. Among non-diabetics, aliskiren
was associated with a statistically significant greater decrease in
NT-proBNP level compared with placebo at 1 and 6 months post-
randomization (P ≤ 0.02), but not 12 months (P ¼ 0.08) (Figure 3).
Plasma renin activity was significantly reduced with aliskiren at each
time point tested (all P, 0.01). Similarly, aliskiren reduced plasma
aldosterone and plasma troponin I levels across all time points, rela-
tive to placebo (all P ≤ 0.04).
By comparison, among diabetics, aliskiren was not associated
with a decrease in NT-proBNP compared with placebo at any time
point tested (all P ≥ 0.10). Aliskiren significantly reduced plasma
aldosterone at 1 month relative to placebo (P ¼ 0.01), but not at 6
or 12 months (P ≥ 0.23). Likewise, diabetics treated with aliskiren
had significant decreases in troponin I at 1 month compared to
placebo (P ¼ 0.02), but not at other time points (P ≥ 0.08). Similar
to patients without DM, diabetics had significant reductions in
plasma renin activity at each time point tested relative to placebo
(all P, 0.01).
Safety
Table 5 displays data for adverse events of special interest among
non-diabetic and diabetic patients. There was a trend towards differ-
ing risk of post-baseline potassium level ≥6 mmol/L with aliskiren by
underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71–1.93; DM:
HR: 2.39, 95% CI: 1.30–4.42; P ¼ 0.07 for interaction). No other
notable interactions were seen (all P ≥ 0.32 for interaction).
Among non-diabetics, aliskiren was associated with significantly
higher rates of investigator-reported renal impairment and hypoten-
sion, but there was no significant difference in rates of treatment dis-
continuation due to these adverse effects. When objective cutoffs
were used to evaluate post-baseline risk of severe hyperkalaemia
(potassium ≥6 mmol/L) or severe renal impairment (eGFR
,30 mL/min/1.73 m2), no significant differences between aliskiren
and placebo were seen.
In contrast to non-diabetics, patients with DM who received alis-
kiren did not demonstrate a higher risk of investigator reported
hyperkalaemia, renal impairment, or hypotension, nor did they
have an increased risk of study drug discontinuation for these
effects. However, using objective measures, diabetic patients were
at significantly increased risk of post-baseline severe hyperkalaemia,
but not severe renal impairment.
Discussion
In the ASTRONAUT trial, nearly 60% of patients had no history of
DM. At baseline, .80% of patients were receiving an angiotensin-
converting enzyme (ACE) inhibitor/ARB and .50% were receiving
a mineralocorticoid receptor antagonist (MRA). The effect of aliski-
ren on the primary endpoint of CV death or HF rehospitalization
within 6 months did not significantly differ by baseline DM status.
However, analysis of 12-month CV death or HF rehospitalization
and all-cause death revealed statistically significant interactions by
baseline DM status with non-diabetic patients tending to experience
favourable outcomes. Among non-diabetics, aliskiren significantly
reduced NT-proBNP through 6 months and plasma renin activity,
troponin I and aldosterone through 12 months, as compared to
placebo. There was a trend towards interaction favouring less risk
of post-baseline potassium ≥6 mmol/L with aliskiren in non-
diabetics as compared to diabetics.
While the above findings regarding HHF patients without DM may
be considered encouraging, they must be viewed in the context of a
subgroup analysis and the corresponding statistical limitations,
Figure 2 Kaplan–Meier analysis of the cumulative event rate of
cardiovascular death or heart failure hospitalization (A) and all-
cause death (B) within 12 months in patients without baseline dia-
betes mellitus.
Figure 1 Kaplan–Meier analysis of the cumulative event rate of
cardiovascular death or heart failure hospitalization within 6
months in patients without diabetes mellitus.
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including a smaller numberof patientsper treatment group and issues
with multiplicity.9 However, this efficacy analysis was protocol pre-
specified. Furthermore, although the ASTRONAUT protocol
planned for the analysis of .26 subgroups of interest, stratifying
patients by underlying DM status was the only analysis to demon-
strate a statistically significant interaction of P, 0.05, albeit for sec-
ondary, not primary, endpoints. While the number of pre-specified
subgroups tested supports the possibility of one or two groups
reaching statistical significance by chance alone, the diabetes findings
in ASTRONAUT are consistent with previous prospective data with
aliskiren,7 thus making coincidence less likely.
Our data extend the current body of knowledge in multiple ways
and serve to generate hypotheses regarding an underlying mechan-
ism for a potential differential impact of aliskiren on outcomes by
DM status. One potential explanation relates to differences in
safety profile. Our results suggest that in non-diabetic patients,
there was a discrepancy between the subjective and objective risk
of the three adverse events of special interest. Although investigators
were more likely to report renal impairment and hypotension in
patients receiving aliskiren, they were no more likely to discontinue
the drug due to these effects, perhaps suggesting they were not
severe. Moreover, rates of post-baseline severe hyperkalaemia and
renal impairment, as assessed by objective laboratory cutoffs, were
no different between treatment arms. These findings contrast with
those of the diabetic cohort where incidence of subjective, investiga-
tor reported adverse events of special interest and corresponding
rates of drug discontinuation did not differ by treatment, yet a
greater risk of post-baseline potassium ≥6 mmol/L was seen with
aliskiren with a trend towards interaction by DM status. Existing
data in diabetics suggest that hyperkalaemia, hypotension, and wor-
sening eGFR with RAAS blockade predict poor prognosis.10,11 In
ASTRONAUT, it is possible that an increased incidence of hyperka-
laemia in diabetics receiving aliskiren, in addition to standard therapy
including an ACE inhibitor/ARB, beta-blocker and MRA, contributed
to poor outcomes by overshadowing any positive effects of the drug.
Likewise, lack of severe hyperkalaemia in non-diabetics may have
allowed favourable effects of the drug to predominate.
A second possible mechanism for improved outcomes with aliski-
ren in non-diabetics is the corresponding biomarker profile. Most
notably, among non-diabetics, aliskiren significantly reduced NT-
proBNP and plasma aldosterone levels compared with placebo
through 6 months. This effect on plasma aldosterone was sustained
and significant at 12 months. In diabetic patients, relative to
placebo, aldosterone was only significantly reduced at 1 month and
NT-proBNP was not significantly reduced at any follow-up time
point. Given that NT-proBNP levels were significantly decreased
over 12 months in the overall ASTRONAUT cohort without
improvements in patient outcomes, it is unlikely that the effect of alis-
kiren on natriuretic peptides alone is responsible for the potential bi-
directional effect of aliskiren by DM status.6 Rather, it is noteworthy
that although absolute levels of plasma aldosterone tended to rise
over time in all patients, this rise was blunted in non-diabetic patients
receiving aliskiren. This significant sustained ability of aliskiren to at-
tenuate increases in aldosterone, the final downstream neurohor-
mone in the RAAS, may have contributed to the lower event rates
in non-diabetics receiving the drug.12 This hypothesis is consistent
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Table 3 Adjudicated causes of death among non-diabetic and diabetic patients
Non-diabetics Diabetics
Adjudicated cause of death, n (%) Aliskiren (n5 489) Placebo (n 5 465) Aliskiren (n5 319) Placebo (n 5 345)
CV death 67 (13.7) 88 (18.9) 67 (21.0) 56 (16.2)
Fatal myocardial infarction 3 (0.6) 6 (1.3) 1 (0.3) 6 (1.7)
Pump failure 23 (4.7) 33 (7.1) 31 (9.7) 23 (6.7)
Sudden death 28 (5.7) 30 (6.5) 18 (5.6) 15 (4.3)
Presumed sudden death 3 (0.6) 1 (0.2) 4 (1.3) 2 (0.6)
Presumed CV death 4 (0.8) 10 (2.2) 7 (2.2) 4 (1.2)
Other CV death 0 0 0 2 (0.6)
Fatal stroke 3 (0.6) 5 (1.1) 3 (0.9) 2 (0.6)
CV procedural 1 (0.2) 0 0 1 (0.3)
Unknown 2 (0.4) 3 (0.7) 3 (0.9) 1 (0.3)
Non-CV death 8 (1.6) 5 (1.1) 10 (3.1) 4 (1.2)
Accidental 1 (0.2) 0 3 (0.9) 0
Pulmonary 0 0 1 (0.3) 0
Infection 3 (0.6) 1 (0.2) 6 (1.9) 2 (0.6)
Malignancy 2 (0.4) 1 (0.2) 0 0
Gastrointestinal 1 (0.2) 3 (0.7) 0 2 (0.6)
Renal 0 0 0 0
Other non-CV death 1 (0.2) 0 0 0
CV, cardiovascular.
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with the established chronic HF paradigm that incremental increases
in RAAS blockade with ACE inhibitors, ARB, and MRA improve
patient outcomes.13– 16 In patients without DM, simultaneous use
of aliskiren with other established RAAS therapies may maximize
RAAS suppression and produce further clinical benefits.
In aggregate, the results of the Aliskiren Trial in Type 2 Diabetes
Using Cardiorenal Disease Endpoints (ALTITUDE) and ASTRO-
NAUT do not support a role for aliskiren in HHF patients already re-
ceiving an ACE inhibitor or ARB, particularly in those with comorbid
DM. However, the potential benefits of aliskiren in non-diabetics
should not be overlooked. Although outcomes in chronic ambulatory
HF have improved in recent decades, treatment and outcomes for
patients admitted to the hospital for HF remain largely unchanged
despite guideline recommended therapy.17–19 Hospital admission
for HF portends a poor prognosis and ASTRONAUT confirmed an
unacceptably high post-discharge event rate among clinically and
haemodynamically stable hospitalized patients.6,20 Novel therapeutics
areurgentlyneeded and our datagenerate thehypothesis that aliskiren
is safe, effective, and associated with a favourable neurohormonal
profile in non-diabetic patients. Further insights may come from the
ongoing long-term Aliskiren Trial on Minimizing Outcomes in Patients
with Heart Failure (ATMOSPHERE).21 In that study, analyses by
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Table 4 Change from baseline in biomarkers among diabetic and non-diabetic patients
Non-diabetic patients Diabetic patients
Time point Treatment n Ratio: endpoint/ baseline;
adjusted geometric
mean (95% CI)
Ratio: aliskiren/
placebo (95% CI)
n Ratio: endpoint/baseline;
adjusted geometric
mean (95% CI)
Ratio: aliskiren/
placebo (95% CI)
NT-proBNP (pg/mL)
Month 1 Aliskiren 405 0.82 (0.76, 0.89) 264 0.92 (0.85–0.99)
Placebo 388 0.93 (0.86, 1.01) 0.88 (0.80, 0.97) 287 0.98 (0.91–1.06) 0.94 (0.85–1.03)
Month 6 Aliskiren 354 0.61 (0.55, 0.68) 215 0.70 (0.62–0.78)
Placebo 324 0.74 (0.66, 0.83) 0.83 (0.71, 0.97) 232 0.79 (0.71–0.88) 0.88 (0.76–1.03)
Month 12 Aliskiren 281 0.58 (0.51, 0.66) 166 0.70 (0.60–0.81)
Placebo 237 0.68 (0.60, 0.78) 0.85 (0.71, 1.02) 188 0.83 (0.72–0.96) 0.84 (0.68–1.03)
Plasma renin activity (ng/mL/h)
Month 1 Aliskiren 306 0.15 (0.12–0.18) 216 0.17 (0.13–0.21)
Placebo 287 1.54 (1.28–1.85) 0.10 (0.08–0.12) 220 1.20 (0.95–1.50) 0.14 (0.10–0.19)
Month 6 Aliskiren 259 0.16 (0.13–0.20) 168 0.20 (0.15–0.25)
Placebo 246 1.27 (1.03–1.56) 0.13 (0.10–0.17) 177 1.17 (0.92–1.49) 0.17 (0.12–0.23)
Month 12 Aliskiren 200 0.23 (0.19–0.30) 124 0.22 (0.17–0.29)
Placebo 170 1.40 (1.10–1.80) 0.17 (0.12–0.23) 133 1.16 (0.89–1.52) 0.19 (0.13–0.27)
Plasma troponin I (ng/mL)
Month 1 Aliskiren 387 0.66 (0.61–0.72) 253 0.75 (0.67–0.84)
Placebo 367 0.77 (0.70–0.84) 0.86 (0.77–0.97) 262 0.90 (0.80–1.00) 0.84 (0.72–0.97)
Month 6 Aliskiren 335 0.64 (0.58–0.71) 208 0.67 (0.60–0.76)
Placebo 306 0.76 (0.68–0.84) 0.84 (0.73–0.96) 209 0.75 (0.67–0.84) 0.90 (0.77–1.05)
Month 12 Aliskiren 262 0.65 (0.58–0.73) 158 0.69 (0.60–0.79)
Placebo 224 0.77 (0.68–0.87) 0.85 (0.73–0.99) 174 0.81 (0.71–0.92) 0.85 (0.71–1.02)
Plasma aldosterone (pmol/L)
Month 1 Aliskiren 145 1.08 (0.93–1.26) 122 1.13 (0.96–1.34)
Placebo 140 1.69 (1.44–1.98) 0.64 (0.52–0.78) 118 1.49 (1.25–1.77) 0.76 (0.61–0.95)
Month 6 Aliskiren 130 1.00 (0.84–1.19) 98 1.53 (1.28–1.82)
Placebo 122 1.64 (1.37–1.97) 0.61 (0.48–0.76) 91 1.53 (1.28–1.83) 1.00 (0.79–1.25)
Month 12 Aliskiren 106 1.28 (1.05–1.57) 72 1.38 (1.12–1.71)
Placebo 89 1.85 (1.49–2.29) 0.69 (0.52–0.92) 76 1.64 (1.32–2.03) 0.84 (0.64–1.12)
CI, confidence interval; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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baseline DM status have again been pre-specified and may further
define the risks and benefits of aliskiren in diabetic and non-diabetic
patients.
The aforementioned features inherent to subgroup analyses con-
stitute the major limitations of this work and these results must be
considered hypothesis generating only. An additional limitation is
the definition of DM used. The presence or absence of underlying
DM was determined solely by the investigator and it was not manda-
tory to use objective criteria such as baseline use of diabetic medica-
tions or previous haemoglobin A1c values. Thus, it is possible that the
DM status reported in ASTRONAUT may not perfectly overlap with
the true biological DM status of this population.
Conclusions
In the pre-specified subgroup of ASTRONAUT patients with and
without DM, the addition of aliskiren to standard therapy in non-
diabetics appeared to improve post-discharge outcomes and bio-
marker profile, and was generally well-tolerated. In contrast, diabetic
patients receiving aliskiren appeared to have worse post-discharge
outcomes. Given the persistently high post-discharge event rate
despite available therapies, future prospective investigations are
encouraged to confirm potential benefits of renin inhibition in a
large cohort of HHF patients without DM.
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Table 5 Adverse events of special interest by treatment group among non-diabetics and diabetics (safety set)
Aliskiren, n (%)
Non-DM (n5 489)
DM (n 5 319)
Placebo, n (%)
Non-DM (n5 465)
DM (n5 345)
Aliskiren vs. Placebo
relative risk (95% CI)
P for interaction
(two-sided)
Adverse event of special interest
Hyperkalaemiaa
Non-DM 96 (19.6) 74 (15.9) 1.23 (0.94–1.62)
DM 73 (22.9) 68 (19.7) 1.16 (0.87–1.56) 0.80
Renal impairment or renal failureb
Non-DM 75 (15.3) 48 (10.3) 1.49 (1.06–2.09)
DM 59 (18.5) 50 (14.5) 1.28 (0.90–1.80) 0.57
Hypotensionc
Non-DM 88 (18.0) 56 (12.0) 1.49 (1.10–2.04)
DM 50 (15.7) 46 (13.3) 1.18 (0.81–1.70) 0.33
Rate of treatment discontinuation due to adverse events
Hyperkalaemiaa
Non-DM 16 (3.3) 10 (2.2) 1.52 (0.70–3.32)
DM 20 (6.3) 13 (3.8) 1.66 (0.84–3.29) 0.85
Renal impairment or renal failureb
Non-DM 19 (3.9) 9 (1.9) 2.01 (0.92–4.39)
DM 13 (4.1) 12 (3.5) 1.17 (0.54–2.53) 0.34
Hypotensionc
Non-DM 18 (3.7) 9 (1.9) 1.90 (0.86–4.19)
DM 11 (3.5) 10 (2.9) 1.19 (0.51–2.76) 0.43
Maximum or minimum post-baseline values
Potassium ≥6 (mmol/L)
Non-DM 32 (6.5) 26 (5.6) 1.17 (0.71–1.93)
DM 31 (9.7) 14 (4.1) 2.39 (1.30–4.42) 0.07
eGFR ,30 (mL/min/1.73 m2)
Non-DM 46 (9.4) 42 (9.0) 1.04 (0.70–1.55)
DM 38 (11.9) 29 (8.4) 1.42 (0.90–2.24) 0.32
aHyperkalaemia and increased blood potassium level.
bAbnormal renal function test, acute renal failure, decreased urine output, increased blood creatinine, acute pre-renal failure, renal impairment, renal failure, decreased glomerular
filtration rate, and increased blood urea.
cDecreased blood pressure, postural dizziness, hypotension, orthostatic hypotension, and procedural hypotension.
CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate.
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